MedTrace Logo

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

NCT02462122 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2020-08-20

Study results available
· View outcomes & findings →

Summary

Safety and Efficacy of IDP-118 in the treatment of plaque psoriasis

Conditions

Interventions

DRUG

IDP-118 Lotion

Lotion

DRUG

IDP-118 Vehicle Lotion

Lotion

Sponsors & Collaborators

  • Dow Pharmaceutical Sciences

    collaborator INDUSTRY

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Binu J Alexander, MD · Valeant Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-19
Primary Completion
2016-11-09
Completion
2016-11-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462122 on ClinicalTrials.gov